MaxCyte (MXCT) grants RSUs and stock options to director

Rhea-AI Filing Summary

Johnston John Joseph reported acquisition or exercise transactions in this Form 4 filing.

MAXCYTE, INC. director John Joseph Johnston received 30,421 restricted stock units, each representing one share of common stock, as part of his annual non-employee director grant. He also received a stock option for 49,579 shares at $1.13 per share, expiring in 2036. The RSUs vest on June 17, 2027, subject to continued service, bringing his direct common stock holdings to 201,581 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Johnston John Joseph

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	49,579	$0.00	--
Grant/Award	Common Stock	30,421	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 49,579 shares (Direct, null); Common Stock — 201,581 shares (Direct, null)

Footnotes (1)

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Key Figures

RSU grant: 30,421 RSUs Option shares: 49,579 shares Option strike price: $1.13 per share +3 more

6 metrics

RSU grant 30,421 RSUs Annual non-employee director equity grant; each RSU equals one common share

Option shares 49,579 shares Stock option underlying common stock granted to director

Option strike price $1.13 per share Exercise price for newly granted stock option

Option expiry 2036-06-16 Expiration date of stock option grant

Shares owned after grants 201,581 shares Director’s direct common stock holdings following RSU award

RSU vesting date 2027-06-17 Vesting date for 30,421 RSUs, subject to continued service

Key Terms

restricted stock units, RSUs, Equity Grant Policy, Stock Option (right to buy)

4 terms

restricted stock units financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Equity Grant Policy financial

"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."

Stock Option (right to buy) financial

"Stock Option (right to buy) listed as a derivative security with an exercise price of 1.1300"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 04:30 PM Accepted by SEC EDGAR 06/22/2026 - 04:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johnston John Joseph

(Last) (First) (Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		A		30,421(1)(2)	A	$0	201,581	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.13	06/17/2026		A		49,579		(2)	06/16/2036	Common Stock	49,579	$0	49,579	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

	/s/ Maher Masoud, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did MaxCyte (MXCT) director John Joseph Johnston report?

John Joseph Johnston reported receiving 30,421 restricted stock units and a stock option for 49,579 shares of MaxCyte common stock as compensation grants on June 17, 2026, rather than open-market purchases or sales.

Were John Joseph Johnston’s MaxCyte (MXCT) transactions open-market buys or sells?

No, the Form 4 shows grant or award acquisitions, not open-market trades. Johnston received restricted stock units and stock options as part of his non-employee director compensation, with no reported purchases or sales for cash in the market.

What are the terms of John Joseph Johnston’s new MaxCyte (MXCT) stock option grant?

Johnston received a stock option for 49,579 shares of MaxCyte common stock with an exercise price of $1.13 per share and an expiration date in 2036, giving him the right to buy shares at that price until expiry.

When do John Joseph Johnston’s MaxCyte (MXCT) restricted stock units vest?

The 30,421 restricted stock units granted to Johnston vest on June 17, 2027, provided he continues to serve as a non-employee director through that date, after which each unit converts into one share of common stock.

How many MaxCyte (MXCT) shares does John Joseph Johnston own after these grants?

Following the reported grants, Johnston directly holds 201,581 shares of MaxCyte common stock. This figure reflects his ownership after receiving the new restricted stock unit award, as disclosed in the Form 4 filing.